The Discounted Cash Flow (DCF) valuation of Mithra Pharmaceuticals SA (MITRA.BR) is (462.57) EUR. With the latest stock price at 0.22 EUR, the upside of Mithra Pharmaceuticals SA based on DCF is -214251%.

Is MITRA.BR a buy or a sell?

Based on the latest price of 0.22 EUR and our DCF valuation, Mithra Pharmaceuticals SA (MITRA.BR) is a sell. Selling MITRA.BR stocks now will result in a potential gain of 214251%.

Note: valuation result may not be accurate due to the company's negative earnings.

	Range	Selected
WACC / Discount Rate	4.4% - 6.7%	5.6%
Long-term Growth Rate	3.0% - 4.2%	3.6%
Fair Price	(3,606.50) - (249.78)	(462.57)
Upside	-1669777.2% - -115737.4%	-214251.0%

0.22 EUR

Stock Price

(462.57) EUR

Fair Price

REVENUE & EXPENSES

CAPEX

D&A

WORKING CAPITAL

TERMINAL VALUE

MITRA.BR DCF Valuation: Revenue & Expenses Forecast

(EUR in millions)		Projections

	12-2023	12-2024	12-2025	12-2026	12-2027	12-2028

Revenue	40	55	87	133	193	267
% Growth	40%	37%	58%	53%	45%	38%

Cost of goods sold	(22)	(29)	(43)	(62)	(86)	(113)
% of Revenue	55%	52%	49%	47%	45%	42%

Selling, G&A expenses	(24)	(33)	(53)	(81)	(117)	(162)
% of Revenue	61%	61%	61%	61%	61%	61%

Research & Development	(63)	(87)	(137)	(209)	(304)	(420)
% of Revenue	157%	157%	157%	157%	157%	157%

Net interest & other expenses	(92)	(127)	(200)	(306)	(445)	(615)
% of Revenue	230%	230%	230%	230%	230%	230%

Tax expense	(12)	34	54	81	117	161
Tax rate	7%	15%	15%	15%	15%	15%

Net profit	(174)	(186)	(293)	(444)	(641)	(882)
% Margin	-432%	-338%	-336%	-334%	-332%	-330%